Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells

Cancer Biology and Therapy

Volumn 14, Issue 5, 2013, Pages 401-410

  Wissing, Michel D ^a,b,c   Mendonca, Janet ^b   Kim, Eunice ^b   Kim, Eugene ^b   Shim, Joong S ^d   Kaelber, Nadine S ^b   Kant, Huub ^b,e   Hammers, Hans ^b   Commes, Therese ^f   Van Diest, Paul J ^c   Liu, Jun O ^d   Kachhap, Sushant K ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIV MONTPELLIER   (France)

Author keywords

Cetrimonium bromide (CTAB); Invasion; Irinotecan; N myc downstream regulated gene 1 (NDRG1); Prostate cancer; Synthetic lethality; Topoisomerase I

Indexed keywords

CETRIMIDE; IRINOTECAN; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; MALE; N MYC DOWNSTREAM REGULATED GENE 1; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

CETRIMONIUM BROMIDE (CTAB); INVASION; IRINOTECAN; N-MYC DOWNSTREAM REGULATED GENE 1 (NDRG1); PROSTATE CANCER; SYNTHETIC LETHALITY; TOPOISOMERASE I;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CETRIMONIUM COMPOUNDS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SURFACE-ACTIVE AGENTS;

EID: 84877858030     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23759     Document Type: Article

References (35)

1. seer.cancer.gov. [Web site]. Table 23.8 Cancer of the Prostate (Invasive): 5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age. Available at: http://seer.cancer.gov/csr/1975-2007/results- merged/sect-23-prostate.pdf. Accessed: August 20, 2012.
2. Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011; 7:208-18; PMID:21200394; http://dx.doi.org/10.1038/nrendo.2010.227.
3. Karayi MK, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis 2004; 7:6-20; PMID:14999233; http://dx.doi.org/10.1038/sj. pcan.4500697.
4. Shoushtari AN, Szmulewitz RZ, Rinker-Schaeffer CW. Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol 2011; 8:333-42; PMID:21522123.
5. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003; 63:1731-6; PMID:12702552.
6. Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, et al. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS One 2007; 2:e844; PMID:17786215; http://dx.doi.org/10.1371/journal. pone.0000844.
7. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, et al. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 2012; 4:93-108; PMID:22246988; http://dx.doi.org/10.1002/emmm.201100190.
8. Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ Jr., et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006; 49:2677-80; PMID:16640327; http://dx.doi.org/10.1021/jm051225t.
9. Sink R, Gobec S, Pečar S, Zega A. False positives in the early stages of drug discovery. Curr Med Chem 2010; 17:4231-55; PMID:20939815; http://dx.doi.org/10.2174/092986710793348545.
10. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002; 62:3950-5; PMID:12124325.
11. Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, et al. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res 2005; 11:3296-302; PMID:15867226; http://dx.doi.org/10.1158/1078-0432.CCR-04-2417.
12. Chen SH, Lin JK, Liu SH, Liang YC, Lin-Shiau SY. Apoptosis of cultured astrocytes induced by the copper and neocuproine complex through oxidative stress and JNK activation. Toxicol Sci 2008; 102:138-49; PMID:18056745; http://dx.doi.org/10.1093/toxsci/kfm292.
13. Zheng Y, Wang LS, Xia L, Han YH, Liao SH, Wang XL, et al. NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. Proteomics 2009; 9:2064-75; PMID:19322780; http://dx.doi.org/10.1002/pmic.200800031.
14. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13:1841-51; PMID:12453851; http://dx.doi.org/10.1093/annonc/mdf337.
15. Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, et al. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol Pharmacol 2009; 76:969-83; PMID:19654225; http://dx.doi.org/10.1124/mol.109.055277.
16. Boca SC, Astilean S. Detoxification of gold nanorods by conjugation with thiolated poly(ethylene glycol) and their assessment as SERS-Active carriers of Raman tags. Nanotechnology 2010; 21:235601; PMID:20463383; http://dx.doi.org/10. 1088/0957-4484/21/23/235601.
17. Hauck TS, Ghazani AA, Chan WC. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small 2008; 4:153-9; PMID:18081130; http://dx.doi.org/10.1002/smll.200700217.
18. Friedl P, Hegerfeldt Y, Tusch M. Collective cell migration in morphogenesis and cancer. Int J Dev Biol 2004; 48:441-9; PMID:15349818; http://dx.doi.org/10.1387/ijdb.041821pf.
19. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008; 105:19579-86; PMID:19020076; http://dx.doi.org/10. 1073/pnas.0809763105.
20. Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 2008; 68:7403-8; PMID:18794128; http://dx.doi.org/10.1158/0008-5472.CAN-08-1449.
21. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr., Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007; 2:263-70; PMID:17432820; http://dx.doi.org/10.1021/cb600362d.
22. Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, et al. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst 2010; 102:1855-73; PMID:21088277; http://dx.doi.org/10.1093/jnci/djq457.
23. Wilson BA, Wang H, Nacev BA, Mease RC, Liu JO, Pomper MG, et al. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S). Mol Cancer Ther 2011; 10:825-38; PMID:21441411; http://dx.doi.org/10.1158/1535-7163.MCT-10-0902.
24. Zhang Y, Byun Y, Ren YR, Liu JO, Laterra J, Pomper MG. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res 2009; 69:5867-75; PMID:19567678; http://dx.doi.org/10.1158/0008-5472. CAN-08-4866.
25. clinicaltrials.gov. [Internet]. Bethesda (MD): US National Institutes of Health (NIH); 2010 [updated 2011 Nov 29; cited 2012 Dec 6]. Available from: http://clinicaltrials.gov/ct2/show/NCT01162135?
26. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448:645-6; PMID:17687303; http://dx.doi.org/10.1038/448645a.
27. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-85; PMID:12606142; http://dx.doi.org/10.1016/S0167-6296(02)00126-1.
28. Song Y, Oda Y, Hori M, Kuroiwa K, Ono M, Hosoi F, et al. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin. Hum Pathol 2010; 41:214-22; PMID:19800102; http://dx.doi.org/10.1016/j.humpath.2009.07.011.
29. Lievano G, Mirochnik Y, Rubenstein M, Shaw M, Guinan P. Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo. Methods Find Exp Clin Pharmacol 1996; 18:659-62; PMID:9121221.
30. Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest New Drugs 1998; 16:353-9; PMID:10426671; http://dx.doi.org/10.1023/A:1006120910380.
31. Caruso RP, Levinson B, Melamed J, Wieczorek R, Taneja S, Polsky D, et al. Altered N-myc downstreamregulated gene 1 protein expression in African-American compared with caucasian prostate cancer patients. Clin Cancer Res 2004; 10:222-7; PMID:14734473; http://dx.doi.org/10.1158/1078-0432.CCR-0604-3.
32. Park KG, Chetty U, Scott W, Miller W. The activity of locally applied cytotoxics to breast cancer cells in vitro. Ann R Coll Surg Engl 1991; 73:96-9; PMID:1708217.
33. Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, et al. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res 2006; 12:5557-69; PMID:17000693; http://dx.doi.org/10.1158/1078-0432.CCR-06-0536.
34. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 2010; 5:e11208; PMID:20585447; http://dx.doi.org/10.1371/journal.pone. 0011208.
35. Piquemal D, Joulia D, Balaguer P, Basset A, Marti J, Commes T. Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating and growth arrested cells. Biochim Biophys Acta 1999; 1450:364-73; PMID:10395947; http://dx.doi.org/10.1016/S0167-4889(99)00056-7.